GENE ONLINE|News &
Opinion
Blog

2021-11-22| Special

Study Advocates Cautious Application of CRISPR in Designing Therapeutics

by Arvind C. Shekhar
Share To
CRISPR is a powerful technology that has enabled easy disruption of desired genes and has revolutionized the field of genome editing. CRISPR-based editing has been considered for various applications in medicine, but it also has its shortcomings such as off-target effects, generation of unexpected chromosomal alterations, or potential immunogenicity.

Studies have demonstrated that DSBs induced during CRISPR-based gene knockout can lead to a DNA damage response mediated by p53, a tumor-suppressor gene that initiates programmed cell death before the cells can become cancerous. Presently it is unclear whether p53 selection can happen broadly across multiple different cell types, and whether stronger p53 selection happens when certain genes or parts of the genome are targeted.

A recent study published in Nature Communications shows that CRISPR-Cas9 based gene-editing can confer a selective advantage to cells harboring mutations in genes associated with cancer irrespective of their cell types.

GO Prime with only $1.49 now

LATEST
Novel RAGE Antagonist Stirs Hopes for Countering Diabetic Complications
2021-12-07
AstraZeneca Blocks Private Equity Buyout of Swedish Pharma Sobi
2021-12-06
Coherent Biopharma, WuXi STA Collab Takes a Crack at Peptide-Drug Conjugates
2021-12-06
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
2021-12-06
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
2021-12-03
Novartis, UCB Take Aim at Parkinson’s Disease Under $1.65 Billion Collab
2021-12-03
Atara Biotherapeutics’ First-In-Class Allogeneic T-Cell Therapy Accepted for EMA Review
2021-12-02
EVENT
2021-12-13
63rd ASH ANNUAL MEETING AND EXPOSITION
Georgia, USA
2021-12-28
BIOHK2021
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!